INVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLC

ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) complied with federal securities laws. On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), revealing that the trial did not demonstrate statistical significance for the endpoint of improving fibrosis while not worsening MASH. Following this news, the pri ...